Addiction. Other psychoactive substance related disorders
Conditions
Interventions
Intervention 1: Intervention group: Pramipexole is started at 0.18 mg twice daily and is gradually titrated upward at weekly intervals to reach the desired therapeutic dose (i.e. the dose which is tol
Sponsors
Kerman University of Medical Sciences
Kerman University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1- Patients who have administered stimulants (i.g. methamphetamine) at least 2 days in the past month. 2- Patients who have negative urine analysis for other addictive substances or the history of co-administration of drugs of abuse for no less than 3 weeks ago 3- Patients who meet the criteria of DSM-V for substance use disorder. 4- Patients who have failed to reduce or abstain currently abused substance at least for 2 times. 5- Patients who are seeking treatment and willing to abstain. 6- Age between 18 to 65 years 7- Patients who provide written informed consent. 8- Patients who have interest and are able to take part in a 4-month treatment phase and a 3-month follow up phase study (overall of 7 months). 9- Patients are only allowed to use pain killers, drugs used for neuropathic pain (gabapentin or pregabaline), and sleep aids (only benzodiazepines and Z-drugs)
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pramipexole's possible effects in reducing relapse of stimulants. Timepoint: 1st, 3rd, 6th month of the study and 2 periods of random sampling. Method of measurement: Questionnaires, Urine samples, Self report. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactShokouh Arjmand
Kerman University of Medical Sciences
Outcome results
None listed